The Cancer and Developmental Biology Program (CDBP) includes 41 faculty distributed in 14 departments in the Washington University School of Medicine and Danforth campuses. Developmental biologists share the hypothesis that cancer often results from fundamental errors in developmental regulatory mechanisms. CDBP investigators use model organisms to study oncogenes, oncogenic processes, developmental pathways, and to test potential cancer therapies. Over the years, fundamental discoveries in developmental biology have led to the identification of new genes and regulatory mechanisms that are involved in the development of malignancies. Fundamental questions being asked by CDBP faculty include: How do cells in different parts of an embryo come to express very different sets of genes? How are such developmental processes programmed in the genome? What mechanisms regulate maintenance and activation of stem cells? What happens when developmental regulatory mechanisms fail? How do mutations in developmental genes cause cancer? How do developmental regulatory mechanisms prevent cancer? These are a few of the questions that are being answered in detail by the application of the powerful techniques of modern cell and molecular biology to developmental systems. CDBP faculty will continue to use these systems to identify and understand the function of genes that can cause cancer or modulate its outcome. Importantly, several studies within the CDBP have led to pharmacological studies with potential translation to the clinic. CDBP faculty and students meet on a regular basis to discuss research activities. Laboratories studying developmental biology utilize many core facilities within the Siteman Cancer Center. These include the Cancer Center Embryonic Stem Cell Core, Multiplexed Gene Analysis Core, Tissue Procurement Core and High Speed Cell Sorter Core. CDBP members will continue to play a key role in cancer and developmental biology education at Washington University School of Medicine and the Siteman Cancer Center. CDBP is supported by $21,568,623 in funding of which $1,520,881 is in NCI funding and $18,161,968 in other peer reviewed funding. During the current funding period, in the last grant period, members of the CDBP published 640 manuscripts, of which 17.66% represent inter-programmatic and 8.28% resulted from intraprogrammatic collaborations.

Public Health Relevance

A modern view of causes of cancer is that cancer often results from fundamental errors in developmental regulatory mechanisms. CDBP faculty are trying to understand these fundamental regulatory mechanisms in an effort to understand the underiying causes of cancer. These efforts are expected to lead to improved diagnostic, prevention and treatment of cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA091842-11S1
Application #
8530552
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
11
Fiscal Year
2012
Total Cost
$2,779
Indirect Cost
$951
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Mostafa, Heba H; Thompson, Thornton W; Konen, Adam J et al. (2018) Herpes Simplex Virus 1 Mutant with Point Mutations in UL39 Is Impaired for Acute Viral Replication in Mice, Establishment of Latency, and Explant-Induced Reactivation. J Virol 92:
Choi, Jaebok; Cooper, Matthew L; Staser, Karl et al. (2018) Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease. Leukemia 32:2483-2494
Bartlett, Nancy L; Costello, Brian A; LaPlant, Betsy R et al. (2018) Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. Blood 131:182-190
Kalas, Vasilios; Hibbing, Michael E; Maddirala, Amarendar Reddy et al. (2018) Structure-based discovery of glycomimetic FmlH ligands as inhibitors of bacterial adhesion during urinary tract infection. Proc Natl Acad Sci U S A 115:E2819-E2828
Yokoyama, Christine C; Baldridge, Megan T; Leung, Daisy W et al. (2018) LysMD3 is a type II membrane protein without an in vivo role in the response to a range of pathogens. J Biol Chem 293:6022-6038
Miller, Jessica; Wang, Steven T; Orukari, Inema et al. (2018) Perfusion-based fluorescence imaging method delineates diverse organs and identifies multifocal tumors using generic near-infrared molecular probes. J Biophotonics 11:e201700232
Song, Wilbur M; Joshita, Satoru; Zhou, Yingyue et al. (2018) Humanized TREM2 mice reveal microglia-intrinsic and -extrinsic effects of R47H polymorphism. J Exp Med 215:745-760
Gauvain, Karen; Ponisio, Maria Rosana; Barone, Amy et al. (2018) 18F-FDOPA PET/MRI for monitoring early response to bevacizumab in children with recurrent brain tumors. Neurooncol Pract 5:28-36
Cruchaga, Carlos; Del-Aguila, Jorge L; Saef, Benjamin et al. (2018) Polygenic risk score of sporadic late-onset Alzheimer's disease reveals a shared architecture with the familial and early-onset forms. Alzheimers Dement 14:205-214
Willet, Spencer G; Lewis, Mark A; Miao, Zhi-Feng et al. (2018) Regenerative proliferation of differentiated cells by mTORC1-dependent paligenosis. EMBO J 37:

Showing the most recent 10 out of 1244 publications